MX2015017124A - Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer. - Google Patents
Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer.Info
- Publication number
- MX2015017124A MX2015017124A MX2015017124A MX2015017124A MX2015017124A MX 2015017124 A MX2015017124 A MX 2015017124A MX 2015017124 A MX2015017124 A MX 2015017124A MX 2015017124 A MX2015017124 A MX 2015017124A MX 2015017124 A MX2015017124 A MX 2015017124A
- Authority
- MX
- Mexico
- Prior art keywords
- capecitabine
- component
- effective amount
- products
- therapeutically effective
- Prior art date
Links
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title abstract 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004117 capecitabine Drugs 0.000 title abstract 2
- 238000011275 oncology therapy Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract 1
- 229960001756 oxaliplatin Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361836899P | 2013-06-19 | 2013-06-19 | |
| PCT/EP2014/062496 WO2014202497A1 (en) | 2013-06-19 | 2014-06-16 | Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015017124A true MX2015017124A (es) | 2016-03-07 |
Family
ID=50976625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015017124A MX2015017124A (es) | 2013-06-19 | 2014-06-16 | Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160129034A1 (enExample) |
| EP (1) | EP3010508B1 (enExample) |
| JP (1) | JP6549107B2 (enExample) |
| KR (1) | KR20160009677A (enExample) |
| CN (1) | CN105263499B (enExample) |
| BR (1) | BR112015030734A2 (enExample) |
| CA (1) | CA2912743A1 (enExample) |
| ES (1) | ES2747073T3 (enExample) |
| MX (1) | MX2015017124A (enExample) |
| PL (1) | PL3010508T3 (enExample) |
| RU (1) | RU2015152175A (enExample) |
| WO (1) | WO2014202497A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021033144A1 (en) * | 2019-08-20 | 2021-02-25 | Intas Pharmaceuticals Ltd. | Oral suspension of capecitabine |
| CN113698435B (zh) * | 2021-08-25 | 2023-09-29 | 中国人民解放军空军军医大学 | 一类含有p53-MDM2抑制剂的四价铂配合物及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007107543A1 (en) * | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
| EP3175853B1 (en) * | 2008-08-04 | 2023-11-01 | Wyeth LLC | Antineoplastic combinations of neratinib and capecitabine |
| US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
-
2014
- 2014-06-16 CN CN201480032428.2A patent/CN105263499B/zh not_active Expired - Fee Related
- 2014-06-16 CA CA2912743A patent/CA2912743A1/en not_active Abandoned
- 2014-06-16 WO PCT/EP2014/062496 patent/WO2014202497A1/en not_active Ceased
- 2014-06-16 KR KR1020157035737A patent/KR20160009677A/ko not_active Ceased
- 2014-06-16 EP EP14731223.5A patent/EP3010508B1/en active Active
- 2014-06-16 PL PL14731223T patent/PL3010508T3/pl unknown
- 2014-06-16 JP JP2016520399A patent/JP6549107B2/ja not_active Expired - Fee Related
- 2014-06-16 RU RU2015152175A patent/RU2015152175A/ru not_active Application Discontinuation
- 2014-06-16 BR BR112015030734A patent/BR112015030734A2/pt not_active IP Right Cessation
- 2014-06-16 MX MX2015017124A patent/MX2015017124A/es unknown
- 2014-06-16 ES ES14731223T patent/ES2747073T3/es active Active
- 2014-06-16 US US14/897,416 patent/US20160129034A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3010508A1 (en) | 2016-04-27 |
| ES2747073T3 (es) | 2020-03-10 |
| BR112015030734A2 (pt) | 2017-07-25 |
| CA2912743A1 (en) | 2014-12-24 |
| RU2015152175A (ru) | 2017-07-24 |
| EP3010508B1 (en) | 2019-07-24 |
| JP2016521760A (ja) | 2016-07-25 |
| HK1213475A1 (zh) | 2016-07-08 |
| US20160129034A1 (en) | 2016-05-12 |
| JP6549107B2 (ja) | 2019-07-24 |
| KR20160009677A (ko) | 2016-01-26 |
| CN105263499B (zh) | 2019-11-15 |
| CN105263499A (zh) | 2016-01-20 |
| PL3010508T3 (pl) | 2019-12-31 |
| RU2015152175A3 (enExample) | 2018-04-02 |
| WO2014202497A1 (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202308496B (en) | Pharmaceutical compositions of therapeutically active compounds | |
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| MX2016006667A (es) | Derivados de pirrolo-pirrolona y su uso como inhibidores. | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| GEAP201914678A (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| WO2015070224A3 (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MX2015017964A (es) | Inhibidores de bromodominio. | |
| MX2015008975A (es) | Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| PH12016500164A1 (en) | Therapeutically active compounds and their methods of use | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| PH12016501788A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| ZA201607489B (en) | Combination comprising a glucocorticoid and edo-s101 | |
| MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX2015012153A (es) | Inhibidores de la quinasa pirrolopirimidina cdk9. | |
| WO2016112304A8 (en) | Furoquinolinediones as inhibitors of tdp2 | |
| BR112015030734A2 (pt) | produto farmacêutico, kit e método de tratamento |